Placebo matching REGN9933 clinical trials

A Master Protocol for a Phase 2 Randomized, Double-blind, Placebo-controlled Study of REGN9933 and REGN7508, Monoclonal Antibodies against Factor XI for Prevention of Venous Thromboembolism in Patients with a Peripherally Inserted Central Catheter (ROXI-CATH).

This study is testing new medicines to help prevent blood clots in people who have a long-term drip called a PICC line. We want to see if these medicines are safe and if they can stop clots from forming. It's a key step in finding better ways to protect patients.